^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ZNF479 mutation + TMB-H

    i
    Other names: ZNF479, Zinc Finger Protein 479, KR19, Zinc Finger Protein Kr19, HKr19, KRAB Zinc Finger Protein KR19, TMB | Tumor Mutational Burden
    Related biomarkers:
    Expression
    Others
    over3years
    [VIRTUAL] Association of ZNF479 mutation with tumor mutation burden and survival in lung cancer patients treated with immune checkpoint inhibitors (ESMO 2021)
    Immune checkpoint inhibitors (ICIs) including atezolizumab, pembrolizumab have shown durable responses and have been approved by FDA. This study shows that ZNF479 mutation may serve as a potential positive biomarker of ICIs in lung cancer since it correlated with higher TMB, up regulation of M1 macrophages, CD8 T cells and down regulation of Myeloid dendritic cells.
    Clinical • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • ZNF479 (Zinc Finger Protein 479)
    |
    TMB-H • ZNF479 mutation + TMB-H • IKZF2 mutation
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab)